Figure 8

Imaging modalities delivery of RNAi therapeutics in cancer therapy and clinical applications

Loutfy H Madkour*

Published: 04 March, 2021 | Volume 5 - Issue 1 | Pages: 005-034

Magnetic resonance imaging (MRI). (a) A schematic illustration of the basic principle of in vivo MR imaging. In general, an MRI scanner consists of three types of coils: the first coil provides a strong homogenous magnetic field, the second coil generates the varying strength of magnetic field in X, Y, and Z directions to encode the spatial position of MR signal and the third coil produces the radio frequency to alter the magnetic dipoles of protons in the subject, generating MR signals to be detected and reconstructed into MR image by computer. MR contrast agents can be labeled onto RNAi therapeutics to track their distribution in vivo through T1 and T2 signal enhancement. (b) Typical contrast agents for MRI, including low molecular-weight paramagnetic compound, T1 CA-loaded vehicle, magnetic nanoparticle, T1-T2 compounds hybrid nanoparticle, and T1 compounds hybrid magnetic nanoparticle. (c) Representative T1-weighted MR images (top) and quantitative T1 maps (down) of a tumor (400 mm3) before and after intravenous injection of siRNA-incorporated nanoplex at the dose of 300 mg/kg. Figures adapted with permission from [143].

" alt="jro-aid1035-g008"class="img-responsive img-rounded " style="cursor:pointer">

Figure 8:

Magnetic resonance imaging (MRI). (a) A schematic illustration of the basic principle of in vivo MR imaging. In general, an MRI scanner consists of three types of coils: the first coil provides a strong homogenous magnetic field, the second coil generates the varying strength of magnetic field in X, Y, and Z directions to encode the spatial position of MR signal and the third coil produces the radio frequency to alter the magnetic dipoles of protons in the subject, generating MR signals to be detected and reconstructed into MR image by computer. MR contrast agents can be labeled onto RNAi therapeutics to track their distribution in vivo through T1 and T2 signal enhancement. (b) Typical contrast agents for MRI, including low molecular-weight paramagnetic compound, T1 CA-loaded vehicle, magnetic nanoparticle, T1-T2 compounds hybrid nanoparticle, and T1 compounds hybrid magnetic nanoparticle. (c) Representative T1-weighted MR images (top) and quantitative T1 maps (down) of a tumor (400 mm3) before and after intravenous injection of siRNA-incorporated nanoplex at the dose of 300 mg/kg. Figures adapted with permission from [143].

Read Full Article HTML DOI: 10.29328/journal.jro.1001035 Cite this Article Read Full Article PDF

More Images

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?